April 5, 2023
Sumitomo Pharma said on April 3 that it will consolidate its seven US subsidiaries into a single company this July. The merger is part of an effort to achieve sustainable growth after its flagship atypical antipsychotic drug Latuda (lurasidone) lost...read more